GlassScriptPhysician profile
Daisy S Andaleon
NPI 1093723413
$10,835.80
in general payments reported to CMS, 2019-2025
35 companies · $1,723 in 2025
The $1,723 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,185 · 2020: $572 · 2021: $1,730 · 2022: $1,236 · 2023: $1,875 · 2024: $1,515 · 2025: $1,723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,023 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,022.70 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,771.11 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,642.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,041.63 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $780.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $737.98 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $676.73 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $651.37 | 2019-2025 | Otezla, Repatha, Prolia |
| Novartis Pharmaceuticals Corporation | $416.66 | 2019-2025 | |
| Astellas Pharma US INC | $407.76 | 2023-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $281.17 | 2020-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $246.24 | 2022-2025 | |
| Abbott Laboratories | $221.84 | 2019-2025 | Freestyle Libre 3, Infinity |
| Glaxosmithkline, LLC. | $215.39 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Boston Scientific Corporation | $192.77 | 2019 | |
| Merck Sharp & Dohme LLC | $185.19 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $151.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $142.41 | 2019-2022 | |
| Dexcom, INC. | $142.11 | 2021-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.95 | 2019-2024 | Xifaxan |
| Amarin Pharma, INC. | $124.74 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $116.39 | 2019-2021 | |
| Recor Medical INC | $98.56 | 2025 | Paradise Ultrasound Renal Denervation System |
| Aimmune Therapeutics, INC. | $93.25 | 2025 | Zenpep |
| Allergan, INC. | $68.74 | 2019 | |
| Cranial Technologies, INC | $57.23 | 2019-2023 | Doc Band |
| Xeris Pharmaceuticals, INC. | $56.28 | 2023-2024 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $35.73 | 2022 | |
| Harmony Biosciences LLC | $29.69 | 2023 | Wakix |
| Genzyme Corporation | $24.15 | 2025 | |
| Electromed, INC. | $22.25 | 2021 | |
| Verona Pharma, INC. | $17.42 | 2025 | Ohtuvayre |
| Smith+Nephew, INC. | $16.22 | 2019 | |
| Vanda Pharmaceuticals INC. | $16.16 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.07 | 2022 | |
| Phadia US INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Andaleon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.